Oncogenic mutated forms of Ras are detected in approximately 15% of cancers, and ERK hyperactivation can be seen in nearly one-third of human cancers, leading to deregulation of the RAS-mitogen-activated protein kinase (MEK)-extracellular-signal-regulated kinase (ERK) signaling pathway [87]. The gene discussed is MAP2K7; the disease is cancer.